Agendia, which makes the MammaPrint test, called the report "disappointing" but thinks it still has a shot at landing wider reimbursement in Germany.
EndoPredict is a kit-based RNA expression test that evaluates 12 genes to assess the aggressiveness of breast cancer on a molecular level, and is set to launch in the US this year.
Contractor Palmetto GBA issued a draft local coverage determination proposing ending coverage of the test based on factors including a recent critical study.
The Medicare contractor is proposing to not cover Vectra DA, but to extend coverage for Prolaris, Xpresys, and DecisionDx-UM under specific circumstances.
The panel's decisions could change the codes diagnostic companies use to bill payors for these tests, which could affect revenue.
In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.
Technology Review points out that a new US presidential science advisor hasn't been selected.
Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.
President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.